The U.S. Food and Drug Administration has granted a fast-tracked review of using a Clovis Oncology drug to treat a wider range of ovarian cancer patients.

The Boulder-based company (Nasdaq: CLVS) seeks approval to use its ovarian cancer drug, rucaparib, as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile.

The FDA says it will make a decision by April 6, 2018, Clovis announced Tuesday.

Completing a review in five months is half the time a fast-tracked FDA review can take, an option regulators have when there’s a chance to speed a promising drug to patients.

Read more at the Denver Business Journal: